

Supporting Information for

**Asymmetric hydrogenation of 3-substituted 2*H*-1,4-benzoxazines
with chiral cationic Ru-MsDPEN catalysts: remarkable counteranion
effect**

Jie Qin,^{a,b} Fei Chen,^a Yan-Mei He,^a Qing-Hua Fan^{*a,c}

^a Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences (CAS), Beijing 100190, P. R. China; E-mail: fanqh@iccas.ac.cn

^b Technical Center, China State Construction Engineering Co., Ltd., No. 15 Linhe Street, Shunyi District, Beijing 101300, P. R. China.

^c Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300071, P. R. China.

Contents


1. General information -----	S2
2. Optimization of conditions for asymmetric hydrogenation -----	S3
3. Synthesis of 3-substituted-2 <i>H</i> -1,4-benzoxazines -----	S9
4. Asymmetric hydrogenation of 3-substituted-2 <i>H</i> -1,4-benzoxazines-----	S14
5. References-----	S22
6. Copy of NMR spectra of reduced products -----	S23
7. HPLC spectra of the reduced products -----	S40

1. General information

Unless otherwise noted, all experiments were carried out under an atmosphere of nitrogen using standard Schlenk techniques or in a nitrogen-filled glovebox. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Model Avance DMX 300 Spectrometer (^1H 300 MHz and ^{13}C 75 MHz, respectively). Chemical shifts (δ) were given in ppm and were referenced to residual solvent or TMS peaks. Optical rotations were measured with PerkinElmer 341 polarimeter. High resolution MS (P-ESI HRMS) were obtained on Bruker Apex IV FTMS spectrometer. HPLC analyses were performed on a Varian Prostar 210 liquid chromatograph. All organic solvents were dried using standard, published methods and were distilled before use. All other chemicals were used as received from Aldrich or Acros without further purification. All Ru-catalysts were prepared according to the published method.¹ 3-Substituted-2*H*-1,4-benzoxazines **1** and **3** were synthesized according to modified literature method.²

2. Optimization of conditions for asymmetric hydrogenation



Table S1 Screening of the solvents for asymmetric hydrogenation of **1a** with *(R,R)-6e*^a



Entry	Solvent	Time (h)	Conv. (%) ^b	Ee (%) ^{c,d}
1	ClCH ₂ CH ₂ Cl	12	>95	19 (<i>S</i>)
2	CH ₂ Cl ₂	12	>95	15 (<i>S</i>)
3	toluene	12	>95	9 (<i>S</i>)
4	MeOH	12	>95	55 (<i>R</i>)
5	EtOH	12	>95	57 (<i>R</i>)
6	<i>i</i> -PrOH	12	>95	67 (<i>R</i>)
7	THF	12	>95	65 (<i>R</i>)
8	MeOH/CH ₂ Cl ₂ (1/1, v/v)	12	>95	45 (<i>R</i>)

^a Reaction conditions: **1a** (0.1 mmol) in solvent (1 mL), *(R,R)-6e* (1.0 mol%), H₂ (50 atm), stirred at 20 °C for 12 h. ^b The conversions were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^c The enantiomeric excesses were determined by chiral HPLC with a chiral OD-H column. ^d The absolute configurations of the products were assigned by comparison of the optical rotations with those in the published literature.


Table S2 Screening of the catalysts for asymmetric hydrogenation of **1a** in THF^a



Entry	Catalyst	X	Conv. (%) ^b	Ee (%) ^{c, d}
1	(R,R)- 6a	OTf	>95	8 (<i>S</i>)
2	(R,R)- 6b	BF ₄	>95	13 (<i>R</i>)
3	(R,R)- 6c	PF ₆	>95	47 (<i>R</i>)
4	(R,R)- 6d	SbF ₆	>95	55 (<i>R</i>)
5	(R,R)- 6e	BArF	>95	65 (<i>R</i>)
6	(R,R)- 6f	(PhO) ₂ PO ₂	92	83 (<i>R</i>)
7	(R,R)-6g	Ph₂PO₂	19	92 (<i>R</i>)

^a Reaction conditions: **1a** (0.1 mmol) in THF (1 mL), catalyst (1.0 mol%), H₂ (50 atm), stirred at 20 °C for 12 h. ^b The conversions were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^c The enantiomeric excesses were determined by chiral HPLC with a chiral OD-H column. ^d The absolute configurations of the products were assigned by comparison of the optical rotations with those in the published literature.


Table S3 Screening of the solvents for asymmetric hydrogenation of **1a** with *(R,R)-6g*^a



Entry	Solvent	Conv. (%) ^b	Ee (%) ^c
1	THF	19	92
2	CF ₃ CH ₂ OH	>95	35
3	CH ₂ Cl ₂	32	82
4	ClCH ₂ CH ₂ Cl	57	88
5	toluene	>95	94

^a Reaction conditions: **1a** (0.1 mmol) in solvent (1 mL), *(R,R)-6g* (1.0 mol%), H₂ (50 atm), stirred at 20 °C for 12 h. ^b The conversions were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^c The enantiomeric excesses were determined by chiral HPLC with a chiral OD-H column.

Table S4 Optimization of conditions for asymmetric hydrogenation of **1a** with *(R,R)-6g*^a



Entry	S/C	H ₂ (atm)	Temp. (°C)	Time (h)	Conv. (%) ^b	Ee (%) ^c
1	100	10	20	12	74	94
2	100	50	20	12	>95	94
3	100	80	20	12	>95	94
4	100	50	40	12	>95	94
5	100	50	0	12	79	94
6	100	50	40	6	>95	94
7	200	50	40	6	>95	94
8	500	50	40	24	>95	94
9	1000	50	40	24	40	93
10	1000	50	40	72	73	93

^a Reaction conditions: **1a** (0.1 mmol) in solvent (1 mL), *(R,R)-6g*. ^b The conversions were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^c The enantiomeric excesses were determined by chiral HPLC with a chiral OD-H column.

Table S5: Screening of the catalysts for asymmetric hydrogenation of **3a** in toluene^a

$\text{3a} \xrightarrow[\text{toluene}]{\text{H}_2, (\text{R},\text{R})\text{-6a-i}} \text{4a} + \text{5a}$

$(\text{R},\text{R})\text{-6a-i}$


$X = \text{OTf}$ (**a**); BF_4 (**b**); PF_6 (**c**);
 SbF_6 (**d**); BArF (**e**);

f

Ar = C_6H_5 (**g**);
Ar = 4- $\text{CH}_3\text{O-C}_6\text{H}_4$ (**h**);
Ar = 3,5-(CH_3)₂ C_6H_5 (**i**).

Entry	Catalyst	X	Conv. (%) ^b	4a:5a^c	Ee (%) ^d 4a/5a
1	(R,R)-6e	BArF	>95	33:67	75/92
2	(R,R)-6c	PF_6	>95	70:30	8/14
3	(R,R)-6a	OTf	>95	89:11	47/0
4	(R,R)-6f	$(\text{PhO})_2\text{PO}_2$	>95	91:9	75/nd
5	(R,R)-6g	Ph_2PO_2	>95	95:5	98/nd
6	(R,R)-6h	$(4\text{-MeO-Ph})_2\text{PO}_2$	>95	97:3	99/nd
7	(R,R)-6i	$(3,5\text{-Me}_2\text{Ph})_2\text{PO}_2$	>95	96:4	98/nd
8^e	(R,R)-6h	(4-MeO-Ph)₂PO₂	>95	97:3	99/nd
9^f	(R,R)-6h	$(4\text{-MeO-Ph})_2\text{PO}_2$	>95	97:3	98/nd


^a Reaction conditions: **3a** (0.1 mmol) in toluene (1 mL), catalyst (1.0 mol%), H_2 (50 atm), stirred at 20 °C for 24 h. ^b The conversions were determined by ^1H NMR spectroscopy of the crude reaction mixture. ^c The product ratios of **4a/5a** were determined by ^1H NMR spectroscopy of the crude reaction mixture. ^d The enantiomeric excesses were determined by chiral HPLC. ^e 0.5 mol% catalyst was used. ^f 0.2 mol% catalyst was used.

Table S6: Optimization of conditions for asymmetric hydrogenation of **3a**^a


Entry	Solvent	H ₂ (atm)	Temp. (°C)	T (h)	Conv. (%) ^b	4a/5a ^c	Ee (%) ^d 4a/5a
1	MeOH	50	20	12	>95	53:47	28/50
2	CH ₂ Cl ₂	50	20	12	>95	97:3	95/nd
3	DCE	50	20	12	>95	97:3	94/nd
4	toluene	50	20	12	>95	98:2	99/nd
5	toluene	50	20	1.5	68	98:2	99/nd
6	toluene	10	20	1.5	30	96:4	99/nd
8	toluene	80	20	1.5	>95	98:2	99/nd
9	toluene	50	40	1.5	>95	97:3	99/nd

^a Reaction conditions: **3a** (0.1 mmol) in toluene (1 mL), (R,R)-**6h** (0.5 mol %). ^b The conversions were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^c The product ratios of **4a/5a** were determined by ¹H NMR spectroscopy of the crude reaction mixture. ^d The enantiomeric excesses were determined by chiral HPLC.


3. Synthesis of 3-substituted-2*H*-1,4-benzoxazines



General procedure:³ To a solution of 2-aminophenol (1.09 g, 10 mmol) in dichloromethane (60 mL) was added 20% aqueous K_2CO_3 solution (40 mL) and $n\text{-Bu}_4\text{NHSO}_4$ (10 mg). Then a solution of substituted 2-bromoacetophenone or (*E*)-1-bromo-4-phenylbut-3-en-2-one (10 mmol) in dichloromethane (25 mL) was added dropwise to the reaction mixture over a period of 15 min. The reaction mixture was stirred at room temperature and monitored by TLC. After the consumption of the starting materials, the reaction mixture was washed by water (50 mL) and brine (50 mL), then the organic layer was separated and dried by anhydrous Na_2SO_4 . The solvent was removed on vacuum and the crude product was purified by column chromatography using dichloromethane as eluent to obtain the corresponding 3-substituted-2*H*-1,4-benzoxazines.




3-phenyl-2*H*-1,4-benzoxazine (1a): Yellow solid; 70% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.95-7.91 (m, 2H), 7.50-7.44 (m, 4H), 7.19-7.14 (m, 1H), 7.07-7.01 (m, 1H), 6.95-6.92 (m, 1H), 5.07 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 158.8, 146.5, 135.6, 133.9, 131.3, 128.9, 128.8, 127.9, 126.6, 122.5, 115.7, 63.0.



3-(4-fluorophenyl)-2*H*-1,4-benzoxazine (1b): Yellow solid; 75% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.95-7.89 (m, 2H),


7.44-7.41 (m, 1H), 7.19-7.12 (m, 3H), 7.06-7.00 (m, 1H), 6.93-6.90 (m, 1H), 5.03 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 166.4, 163.0, 157.5, 146.3, 133.9, 131.8, 131.8, 128.8, 128.8, 128.7, 127.9, 122.5, 116.1, 115.9, 115.7, 62.8.



3-(4-chlorophenyl)-2H-1,4-benzoxazine (1c): Yellow solid; 68% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.88-7.85 (m, 2H), 7.46-7.41 (m, 3H), 7.19-7.14 (m, 1H), 7.06-7.01 (m, 1H), 6.93-6.90 (m, 1H), 5.03 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 157.4, 146.3, 137.4, 133.9, 133.7, 129.2, 129.0, 128.0, 127.9, 122.6, 115.7, 62.8.



3-(4-bromophenyl)-2H-1,4-benzoxazine (1d): Yellow solid; 72% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.81-7.76 (m, 2H), 7.62-7.58 (m, 2H), 7.44-7.41 (m, 1H), 7.19-7.13 (m, 1H), 7.06-7.00 (m, 1H), 6.93-6.90 (m, 1H), 5.02 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 157.5, 146.4, 134.4, 133.7, 132.1, 129.1, 128.1, 128.0, 125.9, 122.6, 115.7, 62.7.




3-(4-methoxyphenyl)-2H-1,4-benzoxazine (1e): Yellow solid; 70% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.91-7.88 (m, 2H), 7.44-7.41 (m, 1H), 7.16-7.10 (m, 1H), 7.05-6.90 (m, 4H), 5.02 (s, 2H), 3.86 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 162.2, 158.3, 146.4, 134.0, 128.4, 128.2, 128.1, 127.6, 122.4, 115.6, 114.3, 62.8, 55.5.




3-(4-trifluoromethylphenyl)-2H-1,4-benzoxazine (1f): Yellow solid; 75% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 8.04-8.01 (m, 2H), 7.74-7.71 (m, 2H), 7.47-7.44 (m, 1H), 7.22-7.16 (m, 1H),


7.07-7.02 (m, 1H), 6.95-6.92 (m, 1H), 5.07 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 157.2, 146.4, 138.7, 133.7, 132.9, 132.5, 129.5, 128.3, 126.9, 125.9, 125.8, 122.7, 115.8, 62.9.




3-([1,1'-biphenyl]-4-yl)-2H-1,4-benzoxazine (1g): Yellow solid; 71% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 8.02-8.00 (m, 2H), 7.73-7.70 (m, 2H), 7.67-7.64 (m, 2H), 7.51-7.46 (m, 3H), 7.43-7.38 (m, 1H), 7.20-7.14 (m, 1H), 6.96-6.93 (m, 1H), 5.10 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 158.4, 146.5, 144.0, 140.2, 134.4, 134.0, 129.1, 128.8, 128.1, 128.0, 127.5, 127.3, 127.1, 122.5, 115.7, 63.0.



3-(3-methoxyphenyl)-2H-1,4-benzoxazine (1h): Yellow solid; 71% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.57-7.56 (m, 1H), 7.47-7.35 (m, 3H), 7.19-7.13 (m, 1H), 7.07-7.00 (m, 2H), 6.94-6.91 (m, 1H), 5.05 (s, 2H), 3.89 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 160.1, 158.6, 146.5, 137.0, 133.9, 129.8, 128.8, 128.0, 122.5, 119.0, 117.6, 115.7, 111.3, 63.1, 55.6.




3-(3-chlorophenyl)-2H-1,4-benzoxazine (1i): Yellow solid; 71% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.96-7.95 (m, 1H), 7.76-7.73 (m, 1H), 7.48-7.38 (m, 3H), 7.20-7.14 (m, 1H), 7.06-7.01 (m, 1H), 6.94-6.90 (m, 1H), 5.03 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 157.3, 146.4, 137.3, 135.2, 133.7, 131.2, 130.1, 129.2, 128.1, 126.7, 124.6, 122.6, 115.8, 62.9.




3-(3,4-dichlorophenyl)-2H-1,4-benzoxazine (1j): Yellow solid; 71% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 8.04-8.03 (m,


1H), 7.72-7.68 (m, 1H), 7.54-7.51 (m, 1H), 7.43-7.40 (m, 1H), 7.20-7.14 (m, 1H), 7.06-7.00 (m, 1H), 6.93-6.89 (m, 1H), 4.99 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 156.1, 146.3, 135.4, 135.3, 133.5, 133.5, 130.8, 129.4, 128.5, 128.1, 125.6, 122.7, 115.8, 62.6.




(E)-3-styryl-2H-1,4-benzoxazine (3a): Yellow solid; 71% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.56-7.53 (m, 2H), 7.43-7.33 (m, 4H), 7.17-7.11 (m, 1H), 7.06-6.99 (m, 3H), 6.92-6.89 (dd, J = 8.0, 1.2 Hz, 1H), 4.92 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 159.0, 146.7, 137.4, 135.6, 134.2, 129.8, 129.1, 128.9, 127.6, 126.9, 122.6, 115.8, 62.2.





(E)-3-(4-fluorostyryl)-2H-1,4-benzoxazine (3b): Yellow solid; 75% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.54-7.49 (m, 2H), 7.36-7.33 (m, 1H), 7.16-6.95 (m, 6H), 6.91-6.88 (m, 1H), 4.89 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 165.2, 161.9, 158.8, 146.7, 135.9, 134.2, 131.9, 129.4, 129.3, 128.9, 127.7, 126.8, 122.6, 116.4, 116.1, 115.8, 62.2.




(E)-3-(4-chlorostyryl)-2H-1,4-benzoxazine (3c): Yellow solid; 80% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.47-7.44 (m, 2H), 7.37-7.33 (m, 3H), 7.16-7.11 (m, 1H), 7.05-6.99 (m, 3H), 6.93-6.88 (m, 1H), 4.89 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 158.7, 146.7, 135.8, 135.5, 134.2, 134.1, 129.4, 129.0, 128.7, 127.8, 127.6, 122.6, 115.8, 62.2.

 **(E)-3-(4-bromostyryl)-2H-1,4-benzoxazine (3d):** Yellow solid; 75% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.54-7.50 (m, 2H), 7.41-7.34 (m, 3H), 7.17-7.11 (m, 1H), 7.04-6.98 (m, 3H), 6.91-6.88 (m, 1H), 4.89 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 158.7, 146.7, 135.8, 134.6, 134.2, 132.3, 129.0, 128.9, 127.8, 127.7, 123.8, 122.7, 115.8, 62.2. HRMS-ESI exact mass calcd. for $\text{C}_{16}\text{H}_{13}\text{BrNO}^+$ ($[\text{M}+\text{H}]^+$) requires m/z 314.01797, found m/z 314.01750.

 **(E)-3-(4-methoxystyryl)-2H-1,4-benzoxazine (3e):** Yellow solid; 78% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.50-7.47 (m, 2H), 7.36-7.33 (m, 1H), 7.14-7.08 (m, 1H), 7.05-6.97 (m, 2H), 6.93-6.86 (m, 4H), 4.88 (s, 2H), 3.83 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 161.0, 159.2, 146.7, 137.0, 134.4, 129.1, 128.5, 128.3, 127.5, 124.8, 122.5, 115.7, 114.6, 62.2, 55.5. HRMS-ESI exact mass calcd. for $\text{C}_{17}\text{H}_{16}\text{NO}_2^+$ ($[\text{M}+\text{H}]^+$) requires m/z 266.11775, found m/z 266.11756.

 **(E)-3-(3,4-dimethoxystyryl)-2H-1,4-benzoxazine (3f):** Yellow solid; 73% yield; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.35-7.31 (m, 1H), 7.14-6.97 (m, 5H), 6.92-6.85 (m, 3H), 4.89 (s, 2H), 3.91 (s, 3H), 3.90 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 159.1, 150.8, 149.5, 146.7, 137.2, 134.4, 128.6, 128.5, 127.5, 125.0, 122.6, 122.1, 115.7, 111.2, 108.8, 62.1, 56.1, 56.0. HRMS-ESI exact mass calcd. for $\text{C}_{18}\text{H}_{18}\text{NO}_3^+$ ($[\text{M}+\text{H}]^+$) requires m/z 296.12850, found m/z 296.12812.


4. Asymmetric hydrogenation of 3-substituted-2*H*-1,4-benzoxazines



A 50 mL glass-lined stainless-steel reactor equipped with a magnetic stirrer bar was charged with Ru-catalyst (0.001 mmol, 0.5 mol%) and the corresponding 3-substituted-2*H*-1,4-benzoxazines (0.2 mmol) in toluene (2 mL) under nitrogen atmosphere in a glove box. The autoclave was closed, and the final pressure of the hydrogen gas was adjusted to 50 atm after purging the autoclave with hydrogen gas several times. The reaction mixture was stirred at 40 °C for 12 h. Then the hydrogen gas was carefully released and the conversion was determined by ^1H NMR spectroscopy after the solvent was evaporated under reduced pressure. The reaction mixture was filtered through a short pad of silica eluted with DCM to give the pure products. The enantiomeric excess of the product was determined by HPLC with a chiral OD-H column.


(R)-3-phenyl-3,4-dihydro-2*H*-1,4-benzoxazine (2a): known compound,³ Yellow oil; 95% yield, 94% ee, $[\alpha]_D^{20} = -134.5$ (*c* 1.0, CHCl_3), {Lit.^[2] $[\alpha]_D^{20} = -118.1$ (*c* 1.0, CHCl_3) for 98% ee of (*R*)-enantiomer}; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.44-7.34 (m, 5H), 6.91-6.683 (m, 2H), 6.77-6.69 (m, 2H), 4.54-4.50 (dd, $J_1 = 2.8$ Hz, $J_2 = 8.6$ Hz, 1H), 4.34-4.29 (dd, $J_1 = 2.9$ Hz, $J_2 =$

10.7 Hz, 1H), 4.06-4.00 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.6, 139.2, 133.9, 128.9, 128.4, 127.3, 121.6, 119.1, 116.7, 115.6, 71.0, 54.3; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t_1 = 9.9 min (major), (*S*) t_2 = 13.7 min (minor).



(*R*)-3-(4-fluorophenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2b):

Yellow oil; 98% yield, 95% ee, $[\alpha]_{\text{D}}^{20} = -139.8$ (*c* 1.0, CHCl_3), {Lit.³ $[\alpha]_{\text{D}}^{20} = +74.8$ (*c* 1.2, CHCl_3) for 88% ee of (*S*)-enantiomer}; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.41-7.36 (m, 2H), 7.12-7.06 (m, 2H), 6.89-6.81 (m, 2H), 6.76-6.67 (m, 2H), 4.51-4.47 (dd, $J_1 = 2.9$ Hz, $J_2 = 8.5$ Hz, 1H), 4.29-4.24 (dd, $J_1 = 3.0$ Hz, $J_2 = 10.6$ Hz, 1H), 4.04-3.94 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 164.4, 161.1, 143.6, 135.1, 135.0, 133.8, 129.0, 128.9, 121.7, 119.2, 116.7, 116.0, 115.7, 115.6, 71.0, 53.6; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t_1 = 9.9 min (major), (*S*) t_2 = 15.4 min (minor).




(*R*)-3-(4-chlorophenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2c):

Yellow oil; 97% yield, 96% ee, $[\alpha]_{\text{D}}^{20} = -131.3$ (*c* 1.0, CHCl_3), {Lit.^[3] $[\alpha]_{\text{D}}^{20} = +59.1$ (*c* 0.7, CHCl_3) for 90% ee of (*S*)-enantiomer}; ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.39-7.32 (m, 4H), 6.87-6.80 (m, 2H), 6.74-6.67 (m, 2H), 4.52-4.48 (dd, $J_1 = 2.8$ Hz, $J_2 = 8.3$ Hz, 1H), 4.28-4.24 (dd, $J_1 = 2.9$ Hz, $J_2 = 10.7$ Hz, 1H), 4.00-3.93 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.6, 137.9, 134.2, 133.7, 129.2, 128.7, 121.7, 119.3, 116.8, 115.6, 70.9, 53.8; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t_1 = 11.6 min


(major), (*S*) $t_2 = 20.4$ min (minor).

(*R*)-3-(4-bromophenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2d):




Yellow oil; 95% yield, 96% ee, $[\alpha]_D^{20} = -111.5$ (*c* 1.0, CHCl₃), {Lit.³ $[\alpha]_D^{20} = +89.5$ (*c* 1.03, CHCl₃) for 89% ee of (*S*)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.55-7.50 (m, 2H), 7.30-7.27 (m, 2H), 6.89-6.81 (m, 2H), 6.76-6.67 (m, 2H), 4.48-4.45 (dd, $J_1 = 2.9$ Hz, $J_2 = 8.3$ Hz, 1H), 4.28-4.23 (dd, $J_1 = 2.9$ Hz, $J_2 = 10.7$ Hz, 1H), 4.00-3.93 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 143.6, 138.3, 133.6, 132.0, 129.0, 122.3, 121.7, 119.3, 117.0, 115.6, 70.7, 53.7; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) $t_1 = 12.6$ min (major), (*S*) $t_2 = 22.5$ min (minor).

(*R*)-3-(4-methoxyphenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2e):




Yellow oil; 96% yield, 98% ee, $[\alpha]_D^{20} = -126.5$ (*c* 1.0, CHCl₃), {Lit.^[2] $[\alpha]_D^{20} = -55.5$ (*c* 1.0, CHCl₃) for 98% ee of (*R*)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.35-7.31 (m, 2H), 6.96-6.92 (m, 2H), 6.89-6.80 (m, 2H), 6.75-6.66 (m, 2H), 4.47-4.43 (dd, $J_1 = 2.8$ Hz, $J_2 = 8.6$ Hz, 1H), 4.28-4.24 (dd, $J_1 = 2.9$ Hz, $J_2 = 10.7$ Hz, 1H), 4.01-3.95 (m, 2H), 3.83 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 159.7, 143.6, 134.1, 131.2, 128.4, 121.5, 119.0, 116.4, 115.5, 114.3, 71.2, 55.4, 53.7; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) $t_1 = 10.5$ min (major), (*S*) $t_2 = 15.9$ min (minor).

(*R*)-3-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2f):




Yellow oil; 97% yield, 92% ee, $[\alpha]_D^{20} = -122.8$ (*c*

1.0, CHCl₃), {Lit.^[3] [α]_D²⁰ = +63.1 (c 1.48, CHCl₃) for 89% ee of (S)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.68-7.66 (m, 2H), 7.55-7.53 (m, 2H), 6.90-6.83 (m, 2H), 6.78-6.70 (m, 2H), 4.60-4.57 (dd, *J*₁ = 2.9 Hz, *J*₂ = 8.1 Hz, 1H), 4.32-4.28 (dd, *J*₁ = 2.9 Hz, *J*₂ = 10.7 Hz, 1H), 4.04-3.98 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 143.6, 143.5, 133.5, 130.9, 130.4, 127.7, 125.9, 125.9, 125.8, 122.3, 121.9, 119.4, 116.9, 115.7, 70.6, 54.0; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t₁ = 11.3 min (major), (*S*) t₂ = 16.4 min (minor).




(*R*)-3-([1,1'-biphenyl]-4-yl)-3,4-dihydro-2*H*-1,4-benzoxazine (2g): Yellow oil; 95% yield, 97% ee, [α]_D²⁰ = -129.2 (c 1.0, CHCl₃), {Lit.^[2] [α]_D²⁰ = -53.4 (c 1.0, CHCl₃) for 98% ee of (*R*)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.67-7.63 (m, 4H), 7.53-7.48 (m, 4H), 7.44-7.39 (m, 1H), 6.95-6.86 (m, 2H), 6.80-6.71 (m, 2H), 4.59-4.55 (dd, *J*₁ = 2.9 Hz, *J*₂ = 8.5 Hz, 1H), 4.38-4.34 (dd, *J*₁ = 2.9 Hz, *J*₂ = 10.7 Hz, 1H), 4.11-4.05 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 143.6, 141.4, 140.7, 138.3, 133.9, 129.0, 127.7, 127.6, 127.2, 121.6, 119.1, 116.7, 115.5, 71.0, 54.0; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*S*) t₁ = 17.7 min (major), (*R*) t₂ = 25.5 min (minor).




(*R*)-3-(3-methoxyphenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2h): Yellow oil; 95% yield, 90% ee, [α]_D²⁰ = -129.8 (c 1.0, CHCl₃), {Lit.^[2] [α]_D²⁰ = +84.6 (c 0.87, CHCl₃) for 87% ee of (*S*)-enantiomer}; ¹H

NMR (300 MHz, CDCl₃): δ (ppm) 7.35-7.30 (m, 1H), 7.02-6.99 (m, 2H), 6.92-6.82 (m, 3H), 6.76-6.68 (m, 2H), 4.50-4.46 (dd, $J_1 = 2.9$ Hz, $J_2 = 8.6$ Hz, 1H), 4.33-4.28 (dd, $J_1 = 2.9$ Hz, $J_2 = 10.7$ Hz, 1H), 4.04-3.98 (m, 2H), 3.84 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 160.1, 143.6, 140.9, 133.9, 129.9, 121.6, 119.6, 119.0, 116.7, 115.5, 113.8, 112.8, 71.0, 55.4, 54.2; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t₁ = 17.3 min (major), (*S*) t₂ = 19.8 min (minor).




(*R*)-3-(3-chlorophenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2i): Yellow oil; 94% yield, 82% ee, $[\alpha]_D^{20} = -123.2$ (c 1.0, CHCl₃), {Lit.^[2] $[\alpha]_D^{20} = +71.0$ (c 1.38, CHCl₃) for 88% ee of (*S*)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.42 (s, 1H), 7.34-7.29 (m, 3H), 6.89-6.82 (m, 2H), 6.76-6.68 (m, 2H), 4.50-4.46 (dd, $J_1 = 2.9$ Hz, $J_2 = 8.3$ Hz, 1H), 4.30-4.26 (dd, $J_1 = 2.9$, $J_2 = 10.7$ Hz, 1H), 4.01-3.94 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 143.6, 141.4, 134.9, 133.6, 130.2, 128.6, 127.4, 125.5, 121.7, 119.3, 116.8, 115.6, 70.7, 53.9. HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t₁ = 11.0 min (major), (*S*) t₂ = 15.3 min (minor).




(*R*)-3-(3,4-dichlorophenyl)-3,4-dihydro-2*H*-1,4-benzoxazine (2j): Yellow oil; 98% yield, 86% ee, $[\alpha]_D^{20} = -117.8$ (c 1.0, CHCl₃), {Lit.^[2] $[\alpha]_D^{20} = +52.9$ (c 1.12, CHCl₃) for 92% ee of (*S*)-enantiomer}; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.48-7.47 (m, 1H), 7.44-7.41 (m, 1H), 7.23-7.19 (m, 1H), 6.85-6.78 (m, 2H), 6.73-6.65 (m, 2H), 4.45-4.41 (dd, $J_1 = 2.9$ Hz, $J_2 = 8.2$ Hz,

1H), 4.24-4.20 (dd, J_1 = 2.9 Hz, J_2 = 10.7 Hz, 1H), 3.95-3.88 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.5, 139.7, 133.3, 133.1, 132.4, 130.9, 129.2, 126.6, 121.8, 119.5, 116.8, 115.7, 70.5, 53.3; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*R*) t_1 = 14.0 min (major), (*S*) t_2 = 23.8 min (minor).




(-)-(E)-3-styryl-3,4-dihydro-2H-1,4-benzoxazine (4a): Yellow oil; 95% yield, 99% ee, $[\alpha]_D^{20} = -34.5$ (*c* 1.0, CHCl_3); ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.41-7.24 (m, 5H), 6.84-6.64 (m, 5H), 6.23-6.15 (m, 1H), 4.32-4.28 (m, 1H), 4.17-4.12 (m, 1H), 4.02-3.96 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.7, 136.3, 133.1, 133.0, 128.8, 128.1, 126.6, 126.5, 121.7, 119.0, 116.7, 115.5, 69.1, 52.4; HPLC (AD-H, elute: Hexane / *i*-PrOH = 90 / 10, detector: 254 nm, flow rate: 1 mL / min), t_1 = 9.8 min (minor), t_2 = 11.1 min (major). HRMS-ESI exact mass calcd. for $\text{C}_{16}\text{H}_{16}\text{NO}^+$ ($[\text{M}+\text{H}]^+$) requires m/z 238.12297, found m/z 238.12264.




(S)-3-phenethyl-3,4-dihydro-2H-1,4-benzoxazine (5a): Yellow solid; m.p. 89-90 °C; yield 91%, 89% ee, $[\alpha]_D^{20} = +82.5$ (*c* 1.0, CHCl_3); ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.31-7.26 (m, 2H), 7.21-7.17 (m, 3H), 6.79-6.71 (m, 2H), 6.66-6.60 (m, 1H), 6.54-6.51 (m, 1H), 4.20-4.16 (m, 1H), 3.89-3.83 (m, 1H), 3.65 (b, 1H), 3.41-3.33 (m, 1H), 2.75-2.70 (m, 2H), 1.83-1.75 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.9, 141.2, 133.3, 128.7, 128.4, 126.3, 121.5, 118.8, 116.6, 115.6, 69.3, 49.3, 33.9, 32.0; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), (*S*) t_1 = 14.4 min (major),

(R) $t_2 = 17.9$ min (minor).




(-)-(E)-3-(4-fluorostyryl)-3,4-dihydro-2H-1,4-benzoxazine

(3b): Yellow oil; 96% yield, 91% ee, $[\alpha]_D^{20} = -28.6$ (c 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.38-7.34 (m, 2H), 7.05-6.99 (m, 2H), 6.85-6.78 (m, 2H), 6.72-6.64 (m, 3H), 6.14-6.06 (m, 1H), 4.31-4.27 (m, 1H), 4.15-4.10 (m, 1H), 4.02-3.96 (m, 1H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 164.3, 161.0, 143.7, 133.1, 132.5, 132.5, 131.8, 128.2, 128.1, 126.3, 126.3, 121.7, 119.1, 116.7, 115.8, 115.6, 69.1, 52.3; HPLC (AD-H, elute: Hexane / *i*-PrOH = 90 / 10, detector: 254 nm, flow rate: 1 mL / min), $t_1 = 10.1$ min (minor), $t_2 = 13.5$ min (major). HRMS-ESI exact mass calcd. for C₁₆H₁₅FNO⁺ ([M+H]⁺) requires m/z 256.11359, found m/z 256.11322.




(-)-(E)-3-(4-chlorostyryl)-3,4-dihydro-2H-1,4-benzoxazine

(3c): Yellow oil; 94% yield, 98% ee, $[\alpha]_D^{20} = -35.2$ (c 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ (ppm) 7.33-7.28 (m, 4H), 6.85-6.78 (m, 2H), 6.73-6.64 (m, 3H), 6.21-6.13 (m, 1H), 4.31-4.27 (m, 1H), 4.16-4.10 (m, 1H), 4.02-3.96 (m, 1H); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 143.7, 134.8, 133.8, 133.0, 131.7, 128.9, 127.8, 127.3, 121.7, 119.1, 116.7, 115.6, 69.0, 52.3; HPLC (AD-H, elute: Hexane / *i*-PrOH = 90 / 10, detector: 254 nm, flow rate: 1 mL / min), $t_1 = 11.2$ min (minor), $t_2 = 15.4$ min (major). HRMS-ESI exact mass calcd. for C₁₆H₁₅ClNO⁺ ([M+H]⁺) requires m/z 272.08405, found m/z 272.08367.




(-)-(E)-3-(4-bromostyryl)-3,4-dihydro-2H-1,4-benzoxazine

e (3d): Yellow oil; 93% yield, 98% ee, $[\alpha]_D^{20} = -32.9$ (*c* 1.0, CHCl_3); ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.24-7.14 (m, 4H), 6.83-6.75 (m, 2H), 6.70-6.56 (m, 3H), 6.17-6.09 (m, 1H), 4.27-4.22 (m, 1H), 4.10-4.04 (m, 1H), 3.98-3.92 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.7, 134.8, 133.8, 133.0, 131.7, 128.9, 127.8, 127.3, 121.7, 119.1, 116.7, 115.6, 69.0, 52.3; HPLC (AD-H, elute: Hexane / *i*-PrOH = 90 / 10, detector: 254 nm, flow rate: 1 mL / min), $t_1 = 12.2$ min (minor), $t_2 = 16.9$ min (major). HRMS-ESI exact mass calcd. for $\text{C}_{16}\text{H}_{15}\text{BrNO}^+$ ($[\text{M}+\text{H}]^+$) requires m/z 316.03343, found m/z 316.03315.



(-)-(E)-3-(4-methoxystyryl)-3,4-dihydro-2H-1,4-benzoxazine (3e):

Yellow oil; 95% yield, 97% ee, $[\alpha]_D^{20} = -38.9$ (*c* 1.0, CHCl_3); ^1H NMR (300 MHz, CDCl_3): δ (ppm) 7.24-7.14 (m, 4H), 6.83-6.75 (m, 2H), 6.70-6.56 (m, 3H), 6.17-6.09 (m, 1H), 4.27-4.22 (m, 1H), 4.10-4.04 (m, 1H), 3.98-3.92 (m, 1H), 3.77 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 143.7, 134.8, 133.8, 133.0, 131.7, 128.9, 127.8, 127.3, 121.7, 119.1, 116.7, 115.6, 69.0, 55.9, 52.3; HPLC (AD-H, elute: Hexane / *i*-PrOH = 90 / 10, detector: 254 nm, flow rate: 1 mL / min), $t_1 = 14.1$ min (minor), $t_2 = 17.6$ min (major). HRMS-ESI exact mass calcd. for $\text{C}_{17}\text{H}_{18}\text{NO}_2^+$ ($[\text{M}+\text{H}]^+$) requires m/z 268.13377, found m/z 268.13321.



(-)-(E)-3-(3,4-dimethoxystyryl)-3,4-dihydro-2H-1,4-benzoxazine (3f):


Yellow oil; 97% yield, 98% ee, $[\alpha]_D^{20} = -40.5$ (*c* 1.0, CHCl_3); ^1H NMR (300 MHz, CDCl_3): δ (ppm) 6.95-6.92 (m, 2H), 6.85-6.78 (m, 3H), 6.71-6.60 (m, 3H), 6.07-5.99 (m, 1H), 4.30-4.26 (m, 1H), 4.12-4.06 (m, 1H),



4.01-3.95 (m, 1H), 3.90 (s, 3H), 3.88 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 149.2, 149.1, 143.6, 133.2, 132.7, 129.3, 124.4, 121.6, 119.9, 118.9, 116.6, 115.5, 111.2, 108.8, 69.2, 55.9, 55.9, 52.4; HPLC (OD-H, elute: Hexane / *i*-PrOH = 80 / 20, detector: 254 nm, flow rate: 1 mL / min), t_1 = 28.2 min (major), t_2 = 37.1 min (minor). HRMS-ESI exact mass calcd. for $\text{C}_{18}\text{H}_{20}\text{NO}_3^+$ ($[\text{M}+\text{H}]^+$) requires m/z 298.14425, found m/z 298.14377.


5. Reference


- [1] G. Sabitha, A. V. S. Rao, *Synth. Commun.* **1987**, *17*, 341.
- [2] M. Rueping, A. P. Antonchick, T. Theissmann, *Angew. Chem. Int. Ed.* **2006**, *45*, 6751.
- [3] K. Gao, C-B. Yu, D-S. Wang, Y-G. Zhou, *Adv. Synth. Catal.* **2012**, *354*, 483.


6. Copy of NMR spectra of reduced products





















































7. HPLC spectra of the reduced products






Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
1	未知	9.87	50.03	221.3	53.3	50.031
2	未知	13.71	49.97	153.5	53.3	49.969
Total			100.00	374.8	106.6	100.000




Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
2	未知	9.86	96.60	888.4	214.4	96.603
1	未知	13.87	3.40	21.7	7.5	3.397
Total			100.00	910.1	222.0	100.000













Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU_Min]	Area % [%]
1	未知	12.83	49.75	117.4	41.7	49.749
2	未知	22.65	50.25	63.2	42.2	50.251
Total			100.00	180.6	83.9	100.000




Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU_Min]	Area % [%]
1	未知	12.59	97.91	511.0	187.3	97.912
2	未知	22.54	2.09	6.7	4.0	2.088
Total			100.00	517.7	191.3	100.000












Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
2	未知	17.59	49.96	108.9	53.9	49.963
1	未知	20.05	50.04	94.9	54.0	50.037
Total			100.00	203.9	107.9	100.000





Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
2	未知	17.33	94.99	361.7	180.5	94.988
1	未知	19.77	5.01	17.8	9.5	5.012
Total			100.00	379.5	190.0	100.000







Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
2	未知	11.25	49.99	212.3	64.6	49.993
1	未知	15.64	50.01	145.6	64.6	50.007
Total			100.00	357.9	129.2	100.000




Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
1	未知	11.01	91.21	1067.5	320.7	91.210
2	未知	15.34	8.79	73.4	30.9	8.790
Total			100.00	1140.9	351.6	100.000













Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
1	未知	11.26	50.05	246.6	55.4	50.054
2	未知	15.40	49.95	180.2	55.3	49.946
Total			100.00	426.8	110.6	100.000




Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
2	未知	11.17	0.74	10.7	2.1	0.743
1	未知	15.36	99.26	917.5	276.1	99.257
Total			100.00	928.2	278.1	100.000







Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
1	未知	14.22	50.07	297.1	84.8	50.069
2	未知	17.87	49.93	235.4	84.5	49.931
Total			100.00	532.5	169.3	100.000



Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU·Min]	Area % [%]
2	未知	14.13	1.48	10.6	2.6	1.476
1	未知	17.63	98.52	480.9	170.6	98.524
Total			100.00	491.5	173.2	100.000



Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
1	未知	28.49	49.97	64.2	69.2	49.972
2	未知	36.85	50.03	49.2	69.3	50.028
Total			100.00	113.4	138.5	100.000



Index	文件名	时间 [Min]	数量 [% 面积]	高度 [mAU]	Area [mAU Min]	Area % [%]
1	未知	28.16	98.93	212.7	236.6	98.931
2	未知	37.10	1.07	2.2	2.6	1.069
Total			100.00	214.9	239.2	100.000